(63) found that ICAM-1 activates platelets in residual tumor tissue after RFA and promotes vascular permeability in TAECs via VE-cadherin and that anti-platelet and anti-ICAM-1 therapy could prevent progression of HCC after RFA. Here, ICAM1 is linked to hepatocellular carcinoma.